Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating restated by equities research analysts at Numis Securities in a report issued on Wednesday. They currently have a GBX 1,300 ($17.96) price target on the stock. Numis Securities’ target price points to a potential upside of 35.59% from the company’s current price.
A number of other brokerages have also recently weighed in on HIK. Morgan Stanley reaffirmed an “equal weight” rating and issued a GBX 1,100 ($15.20) price target on shares of Hikma Pharmaceuticals in a research report on Friday, December 1st. Jefferies Group boosted their price target on Hikma Pharmaceuticals from GBX 1,045 ($14.44) to GBX 1,074 ($14.84) and gave the stock a “hold” rating in a research report on Monday, December 4th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Hikma Pharmaceuticals in a research report on Monday, January 15th. Peel Hunt reaffirmed a “hold” rating and issued a GBX 1,390 ($19.20) price target on shares of Hikma Pharmaceuticals in a research report on Thursday, February 1st. Finally, Barclays cut Hikma Pharmaceuticals to an “underweight” rating and reduced their price target for the stock from GBX 1,500 ($20.72) to GBX 800 ($11.05) in a research report on Thursday, March 1st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of GBX 1,080 ($14.92).
Shares of Hikma Pharmaceuticals (LON HIK) opened at GBX 958.80 ($13.25) on Wednesday. Hikma Pharmaceuticals has a 12-month low of GBX 814.20 ($11.25) and a 12-month high of GBX 2,346 ($32.41). The firm has a market capitalization of $2,300.00 and a PE ratio of 1,956.73.
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.